Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1483-1488

  Miech, Ralph P ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Abortion; Clostridium sordellii; Mifepristone; Septic shock

Indexed keywords

CODEINE; CYTOKINE; ENDOTOXIN; EXOTOXIN; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MIFEPRISTONE; PROGESTERONE RECEPTOR;

ABORTION; CLOSTRIDIUM SORDELLII; CYTOKINE PRODUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HORMONE RESPONSE; HUMAN; IMMUNE RESPONSE; LETHALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

ABORTIFACIENT AGENTS; ABORTION, SEPTIC; CLOSTRIDIUM INFECTIONS; CYTOKINES; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; MIFEPRISTONE; PREGNANCY; RECEPTORS, GLUCOCORTICOID; SHOCK, SEPTIC;

EID: 23944438876     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G189     Document Type: Review

References (49)

1. Donaldson MS, Dorflinger L, Brown SS, Benet LZ. Clinical applications of mifepristone (RU486) and other antiprogestins. Institute of Medicine. Washington, DC: National Academy Press, 1993:1-120.
2. Brouckaert P, Everaerdt B, Fiers W. The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Eur J Immunol 1992;22:981-6.
3. McGregor JA, Soper DE, Lovell G, Todd JK. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol 1989;161:987-95.
4. Bitti A, Mastrantonio P, Spigaglia P, Irri G, Spano AI, Moretti G, et al. A fatal postpartum Clostridium sordellii associated toxic shock syndrome. J Clin Pathol 1997;50:259-60.
5. Rorbye C, Petersen IS, Nilas L. Postpartum Clostridium sordellii infection associated with fatal toxic shock syndrome. Acta Obstet Gynecol Scand 2000;79:1134-5.
6. Danco Laboratories. www.earlyoptionpill.com/pdfs/dancopressl.pdf (accessed 2005 Jul 20).
7. FDA public health advisory. Sepsis and medical abortion, www.fda.gov/ cder/drug/advisory/mifeprex.htm (accessed 2005 Jul 20).
8. Sinave C, LeTemplier G, Blouin D, Leveilli F, Deland E. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002;35:1441-3.
9. Wiebe E, Gjilbert E, Facot F, Shannon C, Winikoff B. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol 2004;104(5 pt 2 suppl):1142-4.
10. Notice of a second report of the same case. Obstet Gynecol 2005;105:673.
11. Opal SM. The clinical relevance of sepsis related to gram-positive bacterial pathogens (abstract 258). 6th World Congress on Trauma, Shock, Inflammation and Sepsis-pathophysiology, immune consequences and therapy. Shock 2004;21(suppl):65.
12. Vega VL, DeMaio A. Isolated macrophages: an ex vivo paradigm to study the contribution of genetics and environment to the inflammatory response. 6th World Congress on Trauma, Shock, Inflammation and Sepsis-pathophysiology, immune consequences and therapy (abstract 281). Shock 2004;21(suppl):71.
13. Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci U S A 1984;81:3879-82.
14. Hogan SF, Ireland K. Fatal acute spontaneous endometritis resulting from Clostridium sordellii. Am J Clin Pathol 1989;91:104-6. Erratum 1989;92:128.
15. Abdulla A, Yee L. The clinical spectrum of Clostridium sordellii bacteraemia: two case reports and a review of the literature. J Clin Pathol 2000;53:709-12.
16. Medzhitov R, Janeway C Jr. Innate immunity. Adv Immunol 2000;343:338-44.
17. Ulevitch R. Therapeutics targeting the innate immune system. Natl Rev Immunol 2004;4:512-20.
18. Alouf JE. Cholesterol-binding cytolytic protein toxins. Int J Med Microbiol 2000;290:351-6.
19. Vouret-Craviari V, Grail D, Flatau G, Pouyssegur J, Boquet P, Van Obberghen-Schilling E. Effects of cytotoxic necrotizing factor 1 and lethal toxin on actin cytoskeleton and VE-cadherin localization in human endothelial cell monolayers. Infect Immun 1999;67:3002-8.
20. Janeway C Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
21. Triantafilou M, Triantafilou K. Receptor cluster formation during activation by bacterial products (abstract 36). 6th World Congress on Trauma, Shock, Inflammation and Sepsis-pathophysiology, immune consequences and therapy. Shock 2004;21 (suppl):9.
22. Sepsis-pathophysiology. www.sepsis.com/overview/pathophys. jsp? reqNavId=1.3 (accessed 2005 Mar 7).
23. Leonhardt A, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription signaling mechanisms. Steroids 2003;68:761-70.
24. Opal SM, Huber CE. The role of interleukin-10 in critical illness. Curr Opin Infect Dis 2000;13:221-6.
25. Ebongll S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immunol 1999;67:6603-10.
26. Lazar G Jr, Lazar G, Agarwal MK. Modification of septic shock in mice by the antiglucocoticoid RU 38486. Circ Shock 1992;36:180-4.
27. Baird DT. Mode of action of medical methods of abortion. J Am Med Women's Assoc 2000;55:121-6.
28. Gaillard RC. Interaction between the hypothalamo-pituitary-adrenal axis and the immunological system. Ann Endocrinol (Paris) 2001;62:155-63.
29. Williamson DR, Lapointe M. The hypothalamic-pituitary-adrenal axis and low-dose glucocorticoids in the treatment of septic shock. Pharmacotherapy 2003;23:514-25.
30. Annane D, Cavaillon JM. Corticosteroids in sepsis: from bench to bedside? Shock 2003;20:197-207.
31. Webster JI, Sternberg EM. Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol 2004;181:207-21.
32. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002;20:125-63.
33. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117:1162-72.
34. Yoshimura A, Lien E, Infalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J Immunol 1999;163:1-5.
35. Kelso A. Cytokines: principles and prospects. Immunol Cell Biol 1998; 67:300-17.
36. Segnitz B, Gehring U. Mechanism of action of a steroidal antiglucocorticoid in lymphoid cells. J Biol Chem 1990;265:2789-96.
37. Hawes AS, Rock CS, Keogh CV, Lowry SF, Galvano SE. In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect Immun 1992;60:2641-7.
38. Swain MG, Appleyard C, Wallace J, Wong H, Le T. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol Gastrointest Liver Physiol 1999; 276:G199-205.
39. Lazar G Jr, Duda E, Lazar G. Effect of RU38486 on TNF production and toxicity. FEBS Lett 1992;308:137-40.
40. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabilol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283:918-24.
41. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-9.
42. Treutiger CJ, Mullins FE, Johansson ASM, Rouhiainen A, Rauvala HME, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003;254:375-85.
43. Opal SM, Huber CE. Bench-to-bedside review: toll-like receptors and their role in septic shock. Crit Care 2002;62:125-36.
44. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-70.
45. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-1.
46. Riedelmann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Natl Med 2003;9:517-24.
47. Meng G, Rutz M, Grabiec M, Schwandner R, Ebel F, Busch DH, et al. Prevention of experimental TLR2 driven shock by application of specific inhibitor proteins (abstract 260). 6th World Congress on Trauma, Shock, Inflammation and Sepsis-pathophysiology, immune consequences and therapy. Shock 2004;21(suppl):65.
48. Chua G, Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004;8:R248-50. Epub 15 Jun 2004, DOI 10.1186/cc2889
49. Donnino MW, Rivers EP, McCord J, Otero R, Goyal N, Jacobsen G, et al. B-type natriuretic peptide in severe sepsis and septic shock. Acad Emerg Med 2005;12(suppl 1):38.